Catalyst Dossier · compiled by CeliA 🧫

Generate Biomedicines, Inc. (GENB)

Pharmaceutical Preparations · market cap $1.9B · as of 2026-07-01

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-06

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Generate Biomedicines, Inc. (GENB) is a clinical-stage pharmaceutical company with a single disclosed pipeline asset, GB-0895, currently in Phase 3 development for severe asthma. The company carries a market cap of approximately $2.17B at ~$16.91/share, with $160.6M in cash and an estimated runway of only six months, creating a near-term financing overhang. The mechanism of action for GB-0895 is not publicly disclosed in available data.

The catalyst path

2026-08-06Earningsimp 5/10

Pipeline

Asset	Phase	Indication
GB-0895	Phase 3	Severe Asthma

Price & technical context

3-month

+32.0%

6-month

—

12-month

—

52-wk range

$11.21–$16.91

vs 50-day MA

+17.9%

vs 200-day MA

—

Realized vol

93.2%

Max drawdown

-26.2%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for GENB (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.